Crawford Thomas Recruiting Named to Inc.’s Power Partner Awards
November 16, 2022 11:28 ET
|
Crawford Thomas Recruiting
ORLANDO, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Crawford Thomas Recruiting, the leading nationwide recruiting and staffing firm, announced it has been honored in Inc. Business Media’s inaugural...
CAR T Cell Therapy Market Size to Hit USD 10.41 Billion by 2027 at 48.96% CAGR – Report by Market Research Future (MRFR)
November 16, 2022 11:00 ET
|
Market Research Future
New York, USA, Nov. 16, 2022 (GLOBE NEWSWIRE) -- CAR T Cell Therapy Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “CAR T Cell Therapy Market...
Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
November 10, 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
Leading PR and Marketing Agency ÜberStrategist Receives Inc.’s Inaugural Power Partner Award - Celebrating Companies That Help Clients Win
November 01, 2022 07:00 ET
|
UberStrategist
ÜberStrategist Joins 252 Top Firms that Support Nation’s Entrepreneurs and Start-Ups, Based on Measurable Commitment, Reliability, Trust, Creativity, Supportiveness, and Key Virtues that Offer Value...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 31, 2022 17:49 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
October 04, 2022 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity...
OneScreen Spotlighted Again on Inc 5000 List of Fastest Growing US Companies 2022
September 26, 2022 16:00 ET
|
OneScreen
SAN DIEGO , Sept. 26, 2022 (GLOBE NEWSWIRE) -- For the second year running, OneScreen is among the fastest growing US firms profiled on the Inc. 5000. Inc. analysts noted that OneScreen has...
Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
September 01, 2022 07:30 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that Rick...
Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market to Grow at a CAGR of ~30% during 2022-2031; Market to Expand Owing to the Rapid Upsurge in Cancer Cases Worldwide
August 23, 2022 08:44 ET
|
Kenneth Research
New York, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Kenneth Research has published a detailed market report on ‘Global Chimeric Antigen Receptor (CAR-T) Cell Therapy Market’ for the forecast period, i.e....